A Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment Decentralization
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The main purpose of this study is to evaluate the impact of a decentralized treatment model on treatment adherence in participants with early-stage human epidermal growth factor receptor 2- positive (HER2+) breast cancer (BC). This study has 2 groups: Group 1: Consistent Travel Burden (Cohorts A, C, and D), will include participants whose adjuvant therapy location does not increase their travel requirements, and Group 2: Increased Travel Burden (Cohort B), will include participants who must travel from a secondary center to a tertiary center to receive their adjuvant therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Diagnoza wczesnego raka piersi HER2-dodatniego w stopniu II lub III.
- •Przeszła operacyjne usunięcie raka z zamiarem całkowitego wyleczenia.
- •Histologicznie potwierdzony rak piersi HER2-dodatni (potwierdzony przed lub po operacji).
✗ Disqualifies
- •Choroby, które mogłyby utrudnić pacjentowi udział w badaniu lub wypełnianie ankiet.
- •Przyjęcie wcześniejszego leczenia (przedoperacyjnego lub pooperacyjnego) raka piersi HER2-dodatniego w miejscu innym niż 10 badanych ośrodków.
- •Pacjentki objęte administracyjnie przez wtórne ośrodki, które rozpoczęły leczenie przedoperacyjne w IORS zamiast w lokalnym ośrodku wtórnym.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 7, 2026
- Sex
- Female only
Locations (10)
Health Centre Loznica
Loznica, Serbia
General Hospital Požarevac
Požarevac, Serbia
Healthcare Centre Bor
Bor, Serbia
Health Centre Kladovo
Kladovo, Serbia
Health Centre ''Sveti Luka'' Smederevo
Smederevo, Serbia
General Hospital Pančevo
Pančevo, Serbia
Institute for Onocology and Radiology of Serbia
Belgrade, Serbia
General Hospital "Dr Laza K. Lazarevic" Sabac
Šabac, Serbia
Health Centre Valjevo
Valjevo, Serbia
General Hospital ''Stefan Visoki'' Smederevska Palanka
Smederevska Palanka, Serbia
Trial contact
Reference Study ID Number: ML46477 https://forpatients.roche.com/ No attachments to email below.
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.